Further, DC-expressed Gal-9 has been leveraged as a treatment outcome biomarker of adoptive cell transfer therapy in stage IV melanoma patients, wherein positivity of Gal-9 in DC or DC-like macrophages corresponded with improved patient survival [134]. Here, LGALS9 is linked to melanoma.